Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Paul Moreton, Ben Kennedy, Guy Lucas, +8

Journal of Clinical Oncology

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

G Hale, Peppy Rebello, Lee Brettman, +11

Blood

Minimal residual disease is an independent predictor for 10-year survival in CLL

Marwan Kwok, Andy C. Rawstron, Abraham Varghese, +6

Blood

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Peter Hillmen, John G. Gribben, George Follows, +13

Journal of Clinical Oncology

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

Andy C. Rawstron, Ben Kennedy, Paul Moreton, +5

Blood

Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia

Abraham Varghese, Andy C. Rawstron, A. John Ashcroft, +2

Clinical Lymphoma & Myeloma

Bone Marrow FailureLaboratory HematologyImmunologyHematologyPathology +4

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, John G. Gribben, George Follows, +11

Blood

B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle

Fiona Bennett, Andy C. Rawstron, Marieth Plummer, +4

British Journal of Haematology

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

Claes Karlsson, Jeanette Lundin, Eva Kimby, +4

British Journal of Haematology

ImmunologyPhase Ii StudyPharmacotherapyMetronomic ChemotherapyDermatology +18

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, +318

Journal of Clinical Oncology